Quantitative KRAS ctDNA Dynamics Predict Early Recurrence After Neoadjuvant Therapy and Surgery in Pancreatic Cancer

Abstract Early recurrence remains prevalent in pancreatic ductal adenocarcinoma (PDAC) despite multimodality treatment. Circulating tumor DNA (ctDNA) is an emerging prognostic biomarker showing promise in detecting minimal residual disease (MRD). Using a high-sensitivity digital droplet PCR (ddPCR) assay, we evaluated KRAS- mutant ctDNA as a marker of MRD associated with early recurrence (< 12 months) in patients with localized PDAC receiving neoadjuvant chemotherapy (NAC), surgery, and adjuvant chemotherapy (AC). KRAS G12D, G12V, and G12R mutations found in cell-free DNA were detected and quantified with maximum variant allele frequency (mVAF). Of 130 enrolled patients, 55 completed NAC and resection. ctDNA was detected a median of 7.6 months before imaging-confirmed recurrence. Postoperative detection KRAS ctDNA was independently associated with worse recurrence-free survival (RFS) (aHR 3.30, 95% CI 1.33–8.21, p = 0.010), and ctDNA clearance after NAC and surgery was independently associated with improved RFS (aHR 0.23, 95% CI 0.06–0.90, p = 0.035). Median cohort mVAF was 0.03%; patients with mVAF above the median had shorter RFS (12.8 vs. 26.3 months) and more frequent early recurrence (p = 0.027). ctDNA-positive patients who received AC remained with worse outcomes than ctDNA-negative patients, suggesting persistent chemotherapy resistance. These data indicated that persistent KRAS ctDNA after NAC and surgery reflects MRD and support sensitive postoperative ctDNA testing to stratify high risk patients for early recurrence, guiding quantitative, longitudinal monitoring. Future studies in adaptive treatment settings may further extend these findings toward ctDNA-guided clinical decision-making.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-10942935/v1
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Quantitative KRAS ctDNA Dynamics Predict Early Recurrence After Neoadjuvant Therapy and Surgery in Pancreatic Cancer

Alex Horowitz, Petra Urgacova, Amy Wells, Akhil Chawla et al.
3 links
Research Square
Pancreatic and Hepatic Oncology Research
preprint

Quantitative KRAS ctDNA Dynamics Predict Early Recurrence After Neoadjuvant Therapy and Surgery in Pancreatic Cancer

Alex Horowitz, Petra Urgacova, Amy Wells, Akhil Chawla, Dominic J. Vitello, Mary Kasparian, Isabel Temosihue, Vishvetha Rengaraju, Nicole Romero, Claire Shen, Anastasia Chibucos, Lily Dale, Krishay Sridalla, Maya Panday, Jasmine Machhi, Madison Cox, Yury Velichko, Qiang Zhang
preprint en

Abstract

Abstract Early recurrence remains prevalent in pancreatic ductal adenocarcinoma (PDAC) despite multimodality treatment. Circulating tumor DNA (ctDNA) is an emerging prognostic biomarker showing promise in detecting minimal residual disease (MRD). Using a high-sensitivity digital droplet PCR (ddPCR) assay, we evaluated KRAS- mutant ctDNA as a marker of MRD associated with early recurrence (< 12 months) in patients with localized PDAC receiving neoadjuvant chemotherapy (NAC), surgery, and adjuvant chemotherapy (AC). KRAS G12D, G12V, and G12R mutations found in cell-free DNA were detected and quantified with maximum variant allele frequency (mVAF). Of 130 enrolled patients, 55 completed NAC and resection. ctDNA was detected a median of 7.6 months before imaging-confirmed recurrence. Postoperative detection KRAS ctDNA was independently associated with worse recurrence-free survival (RFS) (aHR 3.30, 95% CI 1.33–8.21, p = 0.010), and ctDNA clearance after NAC and surgery was independently associated with improved RFS (aHR 0.23, 95% CI 0.06–0.90, p = 0.035). Median cohort mVAF was 0.03%; patients with mVAF above the median had shorter RFS (12.8 vs. 26.3 months) and more frequent early recurrence (p = 0.027). ctDNA-positive patients who received AC remained with worse outcomes than ctDNA-negative patients, suggesting persistent chemotherapy resistance. These data indicated that persistent KRAS ctDNA after NAC and surgery reflects MRD and support sensitive postoperative ctDNA testing to stratify high risk patients for early recurrence, guiding quantitative, longitudinal monitoring. Future studies in adaptive treatment settings may further extend these findings toward ctDNA-guided clinical decision-making.

Research Square
Northwestern University (US), Robert H. Lurie Comprehensive Cancer Center of Northwestern University (US)
Elsa U. Pardee Foundation, National Institutes of Health
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon